The effect of sodium monofluorophosphate plus calcium on vertebral fracture rate in postmenopausal women with moderate osteoporosis a randomized, controlled trial

Annals of Internal Medicine

Volumn 129, Issue 1, 1998, Pages 1-8

  Reginster, Jean Yves ^a   Meurmans, Laurence ^a   Zegels, Brigitte ^a   Rovati, Lucio C ^c   Minne, Helmut W ^b   Giacovelli, Gianpaolo ^c   Taquet, Anne N ^a   Setnikar, Ivo ^c   Collette, Julien ^a   Gosset, Christiane ^a  

^a CHU Centre Ville   (Belgium)

^b Center of Endocrinology   (Germany)

^c Rotta Research Laboratorium   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CARBONATE; FLUOROPHOSPHATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPINE RADIOGRAPHY; VERTEBRA FRACTURE;

EID: 7144261077     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-1-199807010-00001     Document Type: Article

References (24)

1. Farley JR, Wergedal JE, Baylink DJ. Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells. Science. 1983; 222:330-2.
2. 3H 93thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor β. J Bone Miner Res. 1993;8:19-25.
3. Kanis JA. Treatment of symptomatic osteoporosis with fluoride. Am J Med. 1993;95:S53-S61.
4. Heaney RP, Baylink DJ, Johnston CC Jr, Melton LJ 3d, Meunier PJ, Murray TM, et al. Fluoride therapy for the vertebral crush fracture syndrome. A status report. Ann Intern Med. 1989;111:678-80.
5. Riggs BL, Hodgson SF, O'Fallon WM, Chao EY, Wahner HW, Muhs JM, et al. Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med. 1990;322:802-9.
6. Pak CY, Sakhaee K, Adams-Huet B, Piziak V, Peterson RD, Poindexter JR. Treatment of postmenopausal osteoporosis with slow-release sodium fluoride. Final report of a randomized controlled trial. Ann Intern Med. 1995;123:401-8.
7. Mamelle N, Meunier PJ, Dusan R, Guillaume M, Martin JL, Gaucher A, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet. 1988;2:361-5.
8. Meunier PJ, Sebert JL, Reginster JY, Briancon D, Appelboom P, Netter G, et al. Fluoride salts are no better prevention at preventing new vertebral fractures than calcium-vitamin D in postmenopausal osteoporosis: the FAVOS study. Osteoporosis Int. 1998;8:4-12.
9. Kleerekoper M, Peterson EL, Nelson DA, Phillips E, Schork MA, Tilley BC, et al. A randomized trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int. 1991;1:155-61.
10. Riggs BL, Wahner HW, Dunn WL, Mazess RB, Oxford KP, Melton LJ 3d. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981; 67:328-35.
11. Reginster JY, Janssen C, Deroisy R, Zegels B, Albert A, Franchimont P. Bone mineral density of the spine and the hip measured with dual energy x-ray absorptiometry: normal range and fracture threshold for western European (Belgian) postmenopausal females. Clin Rheum. 1995;14:68-75.
12. Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis. Report of a World Health Organization Study Group. Geneva: World Health Organization; 1994.
13. Reginster JY, Compston JE, Jones EA, Kaufman JM, Audran M, Bouvenot G, et al. Recommendations for the registration of new chemical entities used in the prevention and treatment of osteoporosis [Editorial]. Calcif Tissue Int. 1995;57:247-50.
14. Melton LJ 3d, Kan SH, Frye KM, Wahner HW, O'Fallon WM, Riggs BL. Epidemiology of vertebral fractures in women. Am J Epidemiol. 1989;129: 1000-11.
15. Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, et al. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone Miner. 1988;3:335-49.
16. Stein JA, Lazewatski JL, Hochberg AM. Dual-energy x-ray bone densitometer incorporating an internal reference system [Abstract]. Radiology. 1987; 165P:313.
17. Reginster JY. Osteoporose Postménopausique: Traitement Prophylactique. Paris: Masson; 1993.
18. Riggs BL, O'Fallon W, Hodgson S, Chao E, Wahner H, Muhs J, et al. Clinical trial of fluoride in osteoporotic women: extended observation and additional analyses [Abstract], Bone Miner. 1992;17:S74.
19. Parfitt AM. Bone remodelling: relationship to the amount and structure of bone and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ 3d, eds. Osteoporosis: Etiology, Diagnosis, and Management. New York: Raven; 1988:45-93.
20. Delmas PD, Dupuis J, Duboeuf F, Chapuy MC, Meunier PJ. Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride. J Bone Miner Res. 1990;5(Suppl):S143-7.
21. Ericsson Y. Monofluorophosphate physiology: general considerations. Caries Res. 1983; 17:S46-S55.
22. Muller P, Schmid K, Warnecke G, Setnikar I, Simon B. Sodium fluoride-induced gastric mucosal lesions: comparison with sodium monofluorophosphate. Z Gastroenterol. 1992;30:252-4.
23. Warneke G, Setnikar I. Effects of meal on the pharmacokinetics of fluoride from oral monofluorophosphate. Arzneimittelforschung. 1993;43:592-5.
24. Dure-Smith BA, Farley SM, Linkhart SG, Farley JR, Baylink DJ. Calcium deficiency in fluoride-treated osteoporotic patients despite calcium supplementation. J Clin Endocrinol Metab. 1996;81:269-75.